Profile
Settings
Refer your friends
Sign out
BBV154, a candidate for an intranasal Covid vaccine developed by Bharat Biotech, was recently submitted for regulatory clearance in two dosings and with a booster dosage. The company applied for clearance using results from Phase 3 clinical studies of BBV154. Two injections are the typical first dosage. BBV154 is stable between 2 and 8 degrees Celsius, according to Bharat Biotech. Clinical studies have shown it to be safe, well tolerated, and immunogenic.
The BBV154 intranasal vaccination may induce local antibodies in the upper respiratory tract. These may lessen the spread of disease. Two independent and concurrent clinical studies were performed to assess the efficacy of BBV154 as the main dosage and booster dose. More than 3,000 people were tested in Phase III studies using the primary dosage to determine its safety and immunogenicity.
Tests were done at 14 different locations in India. In contrast, more than 800 people were included in investigations of heterologous booster dosage. The term “heterologous booster” refers to the fact that the third or subsequent vaccination dosage is not the same as the first.
This vaccination is designed to be administered through the nasal route. A nasal route is a good option for nations with low and intermediate incomes because of its inexpensive cost.
In collaboration with Washington University, Bharat Biotech has developed a nasal vaccination against BBV154. The vaccine was licensed for use in exceptional circumstances only among those aged 18 and over.
Key takeaways
- New intranasal vaccines are administered without needing a needle (injection).
- It will be a better and safer alternative for nations in the medium income range.
- This vaccination, the manufacturer claims, improves the overall immune response.
- It prevents infection by deactivating IgG, mucosal IgA, and T cell responses.
- This novel viral vector-based intranasal vaccination can be easily produced on a large scale.
BBIL (Bharat Biotech International Limited)
Bharat Biotech is an innovative leader in the biotechnology industry, renowned for its cutting-edge R&D and production. Its goal is to provide vaccines and biotherapeutics that are effective against illnesses and are accessible to as many people as possible. They aim to be at the forefront of biotechnology innovation in the developing markets so that we may be at the forefront of the battle against illness. The BBIL main office is located in the Indian city of Hyderabad. The business is dedicated to researching and producing drugs, vaccines, and other medical supplies. This company has been around since 1996, when it first opened.
Collaboration with Washington University
The novel vaccine was developed by Bharat Biotech in collaboration with Washington University in St. Louis. Bharat Biotech is responsible for developing and producing the product, while a university in the United States created the vector carrying the spike protein and conducted pre-clinical testing. Covid Suraksha, a scheme run by the Department of Biotechnology, contributed funds toward the vaccine’s development.
More details on BBV154
iNCOVACC offers the combined advantage of allowing speedier formulation of variant-specific vaccines and facile nasal administration that allows mass vaccination to defend against developing variations of concern. According to Bharat Biotech, BBV154 (iNCOVACC) is administered by the nose, and it has the potential to generate antibody responses in the upper respiratory tract.
The vaccine will be produced in numerous locations throughout the nation, including Gujarat, Karnataka, Maharashtra, and Telangana, due to its stable 2-8°C storage temperature range.
Since the vaccine would be administered as a nasal drop, it will eliminate the need for needles and syringes, which are now necessary for all current Covid vaccinations. It will also lessen the need for highly skilled medical professionals to provide the injections.
Nearly 3,100 individuals across 14 locations in India took part in the phase III study. The results showed that the vaccine was “safe, well-tolerated, and immunogenic,” as stated by Bharat Biotech. The business also enrolled 875 people in a study to see whether or not the vaccine could be used as a booster for those who had previously received Covaxin or Covishield.
According to the Government’s Cowin site, India has so far provided 213 billion vaccination doses, of which 102 billion are first doses. According to the Union Health Ministry, about 98% of individuals in India had gotten at least one dosage during the third week of July.
The government has launched a vaccination campaign against Covid, which includes the use of vaccinations like Covishield and Covaxin, and the use of Corbevax; other vaccines, such Covovax and Sputnik, are available at private clinics.
BBIL Managing Directors take on BBV154
“We are happy to announce the clearance of iNCOVACC, a worldwide game changer in intra nasal vaccinations technology,” said Dr Krishna Ella, managing director and chairman of Bharat Biotech. Despite the lower ask for COVID-19 vaccines, we have kept developing and researching intranasal vaccines to have ready platform technologies for emerging infectious illnesses.
About Covid 19
In late 2019, individuals with severe respiratory sickness in Wuhan, China, were the first to have SARS-CoV-2, a positive-sense, single-stranded RNA virus, identified from them. When it comes to respiratory viruses, SARS-CoV-2 is closely linked to SARS-CoV and the Middle East respiratory syndrome coronavirus. Coronavirus disease 2019 (COVID-19), caused by an infection with SARS-CoV-2, is a clinical illness characterised by respiratory failure, coagulopathy, gastrointestinal disease, heart disease, and hyperinflammatory syndrome. COVID-19 poses a particularly high mortality risk to the elderly, the immunocompromised, and individuals with specific comorbidities (such as obesity, diabetes, and hypertension). More than Millions of cases were reported, leading to several hundred thousand fatalities and an estimated case-fatality rate of 4% across almost all nations and territories.
